Literature DB >> 2714730

Pharmacokinetics of dextromoramide in surgical patients.

I Pagani1, N Barzaghi, F Crema, E Perucca, D Ego, V Rovei.   

Abstract

The pharmacokinetics of the narcotic analgesic dextromoramide was investigated by means of a specific GC-MS method in 9 patients who were given a single oral dose of the drug (7.5 mg) together with an anticholinergic before undergoing minor orthopedic surgery. Dextromoramide was rapidly absorbed from the gastrointestinal tract, with peak plasma levels between 68 and 177 micrograms/L usually achieved within 0.5-4.0 h after dosing. In 5 patients, the decline of plasma concentrations after the peak followed a biphasic pattern, with half-lives of 0.4-1.6 h for the first phase and 6.3-21.8 h for the terminal phase. In the remaining patients, no clear-cut biphasic pattern was seen and half-lives calculated over the period between 4 h and 10 h after administration ranged from 1.5 to 4.7 h. Apparent clearance and volume of distribution values ranged from 0.06 to 0.36 1.h-1.kg-1 and from 0.6 to 2.4 l.kg-1, respectively. Less than 0.06% of the dose was excreted unchanged in urine within 8 h of administration. The concentration of the drug in a CSF sample collected 1 h after dosing was below the limit of detection (2 micrograms/L) in all subjects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714730     DOI: 10.1111/j.1472-8206.1989.tb00027.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

1.  Determination and pharmacokinetics of dextromoramide in methadone maintenance therapy.

Authors:  J G Ufkes; J W de Vos; G H van Brussel
Journal:  Pharm World Sci       Date:  1998-04

2.  Chemoenzymatic Synthesis of Optically Active Ethereal Analog of iso-Moramide-A Novel Potentially Powerful Analgesic †.

Authors:  Paweł Borowiecki
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.